(Reuters) – British healthcare investment firm Syncona said on Monday Novartis has stopped the development of experimental eye treatment, GT005, which would result in payments write-off of 54.5 million pounds ($68.23 million) for Gyroscope Holdings Limited.
($1 = 0.7987 pounds)
(Reporting by Radhika Anilkumar in Bengaluru;Editing by Dhanya Ann Thoppil)
